NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
Loading market information…
NSE · ENTERO.NS · INR
Stock price, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Entero Healthcare Solutions Limited’s quoted price sits in the upper half of its reported 52-week range, 18.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Entero Healthcare Solutions Limited’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ₹11.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Entero Healthcare Solutions Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related products, including pharmaceuticals, surgical instruments, medical equipment, over-the-counter remedies, nutritional supplements, and vaccines. Its extensive client base spans retail pharmacies, hospitals, nursing homes, and various healthcare clinics throughout the country.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:51 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | May 27, 2025 | ₹5.90-11.94% vs estimate | ₹13.39B-4.93% vs estimate |
|---|
| Q3 2025 | Feb 12, 2025 | ₹5.80 | ₹13.59B-1.44% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ₹5.40 | ₹13.01B+8.95% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
₹9,780.00+₹116.00 (+1.2%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
₹4,613.40+₹33.40 (+0.73%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
₹2,405.50+₹161.50 (+7.2%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹1,245.50+₹61.10 (+5.16%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
₹8,448.00+₹248.00 (+3.02%)
Apollo Hospitals Enterprise Limited’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
₹840.10-₹33.70 (-3.86%)
Remus Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.14% below the high.
₹182.00+₹4.82 (+2.72%)
QMS Medical Allied Services Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.05% below the high.
